Temporary eosinophilia is a potential adverse reaction of monoclonal antibody therapies in the treatment of a variety of type 2 inflammatory conditions, including asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). The pathophysiology, epidemiology, and clinical significance of eosinophilia and eosinophilic adverse reactions following the initiation of biologic therapy are unclear.
Objectives
To describe the postmarketing, eosinophilic adverse reactions with clinical significance in patients treated with the 3 biologic therapies approved by the U.S. Food and Drug Administration (FDA) for CRSwNP: dupilumab, omalizumab, and mepolizumab.
Methods
The FDA Adverse Event Reporting System (FAERS) Public Dashboard was searched for eosinophilic adverse reactions related to dupilumab, omalizumab, and mepolizumab treatments from November 2004 to December 2022. Data regarding each of the eosinophilic adverse reactions were extracted and analyzed.
Results
A total of 218, 270, and 134 reports of eosinophilic adverse reactions were reported among patients who were treated with dupilumab, omalizumab, and mepolizumab, respectively. The most common eosinophilic adverse reaction was eosinophilic granulomatosis with polyangiitis (338 patients), followed by eosinophilic respiratory tract reactions (158 patients). The most common indication for biological treatment among the reaction groups was asthma.
Conclusions
Eosinophilic adverse reactions are rare but consequential complications of biological treatment. They are more common among patients treated for asthma and chronic rhinosinusitis with nasal polyposis. Measuring and monitoring blood eosinophil levels may be appropriate in specific clinical instances when patients are started on different biologic therapies for type 2 inflammatory conditions.
fda, cder. HIGHLIGHTS OF PRESCRIBING INFORMATION. 2019 [cited 2022 Nov 16]. Available from: www.fda.gov/medwatch.
4.
KlionAD. Eosinophilia: A pragmatic approach to diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2015;2015(1):92–97. Available from: https://pubmed.ncbi.nlm.nih.gov/26637706/ [cited 2022 Nov 16].
5.
fda, cder. HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2023 Feb 16]. Available from: www.fda.gov/medwatch.
6.
CastroMCorrenJPavordID, et al.Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. Available from: https://pubmed.ncbi.nlm.nih.gov/29782217/ [cited 2022 Nov 16].
7.
WenzelSCastroMCorrenJ, et al.Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. Available from: https://pubmed.ncbi.nlm.nih.gov/27130691/ [cited 2022 Nov 16].
8.
RabeKFNairPBrusselleG, et al.Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. Available from: https://pubmed.ncbi.nlm.nih.gov/29782224/ [cited 2022 Nov 16].
9.
WechslerMEFordLBMasperoJF, et al.Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): An open-label extension study. Lancet Respir Med. 2022;10(1):11–25. Available from: https://pubmed.ncbi.nlm.nih.gov/34597534/ [cited 2022 Nov 16].
10.
BachertCHanJKDesrosiersM, et al.. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:https://doi.org/10.1016/S0140-6736(19)31881-1
11.
SimpsonELBieberTGuttman-YasskyE, et al.Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. Available from: https://pubmed.ncbi.nlm.nih.gov/27690741/ [cited 2022 Nov 16].
12.
ThaçiDSimpsonLEDeleuranM, et al.Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. Available from: https://pubmed.ncbi.nlm.nih.gov/31109652/ [cited 2022 Nov 16].
13.
BlauveltAde Bruin-WellerMGooderhamM, et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. Available from: https://pubmed.ncbi.nlm.nih.gov/28478972/ [cited 2022 Nov 16].
14.
BeckLAThaçiDDeleuranM, et al.Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567–577. Available from: https://pubmed.ncbi.nlm.nih.gov/32557382/ [cited 2022 Nov 16].
15.
HiranoIDellonESHamiltonJD, et al.Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.e10. Available from: https://pubmed.ncbi.nlm.nih.gov/31593702/ [cited 2022 Nov 16].
16.
ThaçiDSimpsonELBeckLA, et al.Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. Available from: https://pubmed.ncbi.nlm.nih.gov/26454361/ [cited 2022 Nov 16].
17.
MassanariMHolgateSTBusseWWJimenezPKianifardFZeldinR. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med. 2010;104(2):188–196. Available from: https://pubmed.ncbi.nlm.nih.gov/19846286/ [cited 2023 Feb 16].
18.
PouliquenIJKornmannOBartonSvPriceJAOrtegaHG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015. Available from: /pmc/articles/PMC4647865/ [cited 2023 Feb 16].
WechslerMEKlionADPaggiaroP, et al.Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. Available from: https://pubmed.ncbi.nlm.nih.gov/35636689/ [cited 2022 Nov 15].
21.
MasperoJFCardonaGSchonffeldtP, et al.Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: Phase 3 LIBERTY ASTHMA QUEST study. J Asthma. 2023;60(5):981–990. Available from: https://pubmed.ncbi.nlm.nih.gov/36066123/ [cited 2022 Nov 16].
22.
YamazakiKNomizoTHatanakaKHayamaNOgumaTAsanoK. Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab. Journal of Allergy and Clinical Immunology: Global. 2022;1(3):180–182.
23.
IwaseRIshiguroTFujitaKIshibashiSYokotaT. Dupilumab for atopic dermatitis, a possible risk factor of juvenile ischemic stroke: A case report. J Stroke Cerebrovasc Dis. 2020;29(6):104763. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis
24.
MURAG S, MELEHANI J, FILSOOF D, NADEAU K, SHARON CHINTHRAJAH R. . Dupilumab unmasks eosinophilic granulomatosis with polyangiitis. Chest. 2021;160(4):A8–A9. Available from: http://journal.chestnet.org/article/S0012369221015166/fulltext [cited 2022 Oct 19].
25.
IkedaMOhshimaNKawashimaMShiinaMKitaniMSuzukawaM. Severe asthma where eosinophilic granulomatosis with polyangiitis became apparent after the discontinuation of dupilumab. Intern Med. 2022;61(5):755–759. Available from: https://pubmed.ncbi.nlm.nih.gov/34393172/ [cited 2022 Oct 19].
26.
PersaudPKarmaliRSankarPMajidM. Dupilumab-associated eosinophilic granulomatosis with polyangiitis. Cureus. 2022;14(8):e27670.
27.
TanakaSTsujiTShiotsuSYubaTHiraokaN. Exacerbation of eosinophilic granulomatosis with polyangiitis after administering dupilumab for severe asthma and eosinophilic rhinosinusitis with nasal polyposis. Cureus. 2022;14(5):e25218.
28.
DescampsVDeschampsLel KhalifaJ, et al.Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res. 2021;79:100821. Available from: https://pubmed.ncbi.nlm.nih.gov/33984814/ [cited 2022 Oct 19].
29.
LommatzschMStollPWinklerJ, et al.Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia. Allergy. 2021;76(9):2920–2923. Available from: https://pubmed.ncbi.nlm.nih.gov/34047387/ [cited 2022 Oct 19].
30.
EgerKPetLWeersinkEJMBelEH. complications of switching from antieIL-5 or antieIL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021;9(7):2913–2915. Available from:.https://doi.org/10.1016/j.jaip.2021.02.042[cited 2022 Oct 19].
31.
CaminatiMOlivieriBDamaA, et al.Dupilumab-induced hypereosinophilia: Review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022;16(7):713–721. Available from: https://pubmed.ncbi.nlm.nih.gov/35703018/ [cited 2022 Oct 21].
32.
AdachiMKozawaMYoshisueH, et al.Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respir Med. 2018;Aug(141):56–63. Available from: https://pubmed.ncbi.nlm.nih.gov/30053141973/ [cited 2023 Feb 16].
33.
RuppertAAverousGStanciuD. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008;121(1):253–254. doi:https://doi.org/10.1016/j.jaci.2007.10.040
34.
BastaFMazzucaCNuceraESchiavinoDAfeltraAIncalziRA. Omalizumab in eosinophilic granulomatosis with polyangiitis: Friend or foe? A systematic literature review. Clin Exp Rheumatol. 2020;124(2):214–220. Available from: https://www.clinexprheumatol.org/article.asp?a=14506 [cited 2023 Feb 16].
35.
Omalizumab for asthma. N Engl J Med.2006;355(12):1281–1282.
36.
BargagliERottoliP. Omalizumab treatment associated with Churg-Strauss vasculitis. Int Arch Allergy Immunol. 2008;145(3):268. Available from: https://pubmed.ncbi.nlm.nih.gov/17921677/ [cited 2023 Feb 16].
37.
NazirSTachamoNFareedySBKhanMSLohaniS. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol. 2017;118(3):372–374.e1. Available from: https://pubmed.ncbi.nlm.nih.gov/28094120/ [cited 2023 Feb 16].
38.
CHMP. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS.
39.
BargagliEMadioniCOlivieriCPenzaFRottoliP. Churg-Strauss vasculitis in a patient treated with omalizumab. Journal of Asthma. 2008;45(2):115–116.
40.
BorekciSAydinOHatemiGGemiciogluB. Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report. Int J Immunopathol Pharmacol. 2015;28(1):134–137. Available from: https://pubmed.ncbi.nlm.nih.gov/25816417/ [cited 2023 Feb 23].
41.
CazzolaMMuraMSegretiAMatteiMARoglianiP. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome?Allergy. 2009;64(9):1389–1390. Available from: https://pubmed.ncbi.nlm.nih.gov/19392997/ [cited 2023 Feb 23].
SpinaMFMiadonnaA. Role of omalizumab and steroids in Churg-Strauss syndrome. J Allergy Clin Immunol. 2009;124(3):600–601. Available from: https://pubmed.ncbi.nlm.nih.gov/19631973/ [cited 2023 Feb 23].
44.
CisnerosCSegrellesG. LHJ of, 2013 undefined. Churg-Strauss syndrome in a patient treated with omalizumab. pubmed.ncbi.nlm.nih.gov. [cited 2023 Feb 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/24654320/
45.
OriguchiTIchinoseKTamaiMNakamuraHKawakamiAEguchiK. Omalizumab for asthma. N Engl J Med. 2006;355(6):1281–1282. Available from: https://cir.nii.ac.jp/crid/1573668925361666176 [cited 2023 Feb 23].
46.
RuppertAMAverousGStanciuD, et al.Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008;121(1):253–254. Available from: https://pubmed.ncbi.nlm.nih.gov/18206510/ [cited 2023 Feb 23].
47.
TanRACorrenJ. Safety of omalizumab in asthma. Expert Opin Drug Saf. 2011;10(3):463–471. Available from: https://pubmed.ncbi.nlm.nih.gov/21401438/ [cited 2023 Feb 23].
48.
CorrenJCasaleTBLanierBBuhlRHolgateSJimenezP. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788–797. Available from: https://pubmed.ncbi.nlm.nih.gov/19302249/ [cited 2023 Feb 23].
49.
HanJKBachertCFokkensW, et al.SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–1153. doi:https://doi.org/10.1016/S2213-2600(21)00097-7
50.
DupinCBelhadiDGuilleminaultL, et al.Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. [cited 2022 Nov 17].
51.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS.
52.
hedidVVijayvargiyaPCamilleriM. Advantages and limitations of the federal adverse events reporting system in assessing adverse event reporting for eluxadoline. Clin Gastroenterol Hepatol. 2018;16(3):336–338. doi:https://doi.org/10.1016/j.cgh.2017.11.025
